[{"from": "human", "value": "Please give me some details about this molecule. [C][C][=C][Branch2][Ring2][Branch2][C][=C][C][=C][Ring1][=Branch1][C][=C][Branch2][Ring1][O][N][Ring1][Branch1][C][C@H1][Branch1][C][C][N][C][C][N][Branch1][Branch1][C][C][Ring1][=Branch1][S][=Branch1][C][=O][=Branch1][C][=O][C][C][#N][C][N][C][C][C][Branch1][Branch1][C][C][Ring1][=Branch1][N][C][=C][C][=C][Branch1][=C][S][C][Ring1][Branch1][=N][C][=Branch1][Ring2][=N][Ring1][=Branch2][N][C][C][C][Branch1][C][F][Branch1][C][F][F]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) fusion protein, with potential antineoplastic activity. Upon oral administration, ziftomenib prevents the interaction between the two proteins menin and MLL, and thus the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth and proliferation of certain kinds of leukemia cells."}]